Mitchell Grant is a self-taught investor with over 5 years of experience as a financial trader. He is a financial content strategist and creative content editor. Timothy Li is a consultant, accountant ...

Results from the PATHFINDER 2 trial of Grail's blood test for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology. The Galleri ...

Christina Majaski writes and edits finance, credit cards, and travel content. She has 14+ years of experience with print and digital publications. Khadija Khartit is a strategy, investment, and ...

U.S. Dollar Index slips as traders await Powell's speech and Friday's core PCE inflation data for rate direction clues. Fed's Musalem warns there's "limited room" for further cuts, calling for caution ...

The 13th Statistical Forum, themed “<em>Measuring Cross-border Economic and Financial Linkages in a Dynamic World</em>,” will be held on November 19–20, 2025 ...

Shares of Grail have quintupled this year to nearly $90, as investors waited for news about the Pathfinder 2 study of its cancer-detecting blood test. Management hinted this summer the numbers were ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...